Background -Research on the cost of care of patients with cystic fibrosis is scarce. The aim of this study was to estimate the costs using age-specific medical consumption from real patient data. Methods -The age-specific medical consumption ofpatients with cystic fibrosis in The Netherlands in 1991 was estimated from a survey of medical records and a patient questionnaire. A distinction was made between costs of hospital care, hospital and non-hospital medication, and home care. Costs per year were obtained by multiplying the yearly amount of care and the costs per unit. Results -On average the annual cost of a patient with cystic fibrosis in 1991 was £10 908 (hospital care 42%, medication 37%, home care 20%). The cost of care of cystic fibrosis in The Netherlands, with approximately 1000 patients, is estimated at £10-9 million per year, which is 0 07% of the total health care budget. The cost of care of a patient up to the age of 35 is estimated at £614 587. When year-to-year survival is taken into account and future costs are discounted to the year of birth with a yearly discount rate of 5%, the cost of care of a patient with cystic fibrosis is estimated at £164365 for 1991. This estimate will be used in a prospective evaluation of screening for cystic fibrosis carriers. Conclusions -The cost of care of patients with cystic fibrosis estimated by age-specific medical consumption of real patients is higher than that estimated by non-agespecific medical consumption and/or expert opinions.
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(Thorax 1996;51:298-301) screening for carriers of the cystic fibrosis gene. The cost of care analysis presented here is part of a research project in which the costs, effects, and savings of screening for carriers of the cystic fibrosis gene in The Netherlands are estimated.' We decided not to use data from the literature because we wanted to have agespecific cost estimates using primary data rather than using non-age-specific data and expert opinions.
The aim of the cost of care analysis is to estimate the following quantities using data collected from medical patient records and a patient questionnaire: (1) the age-specific medical consumption and medical costs ofpatients, and a breakdown of these costs into costs of hospital care, hospital and non-hospital medication, and home care with separate estimates for the (pre)terminal disease stage; (2) the lifetime medical costs of a patient by combining age-specific medical costs with recent survival figures of the Dutch cystic fibrosis registration'; and (3) the cost of care of cystic fibrosis in The Netherlands by combining age-specific medical consumption with the number and age distribution of patients in The Netherlands.'
The estimate of the lifetime costs of medical consumption of patients with cystic fibrosis will be used for cost-effectiveness calculations of nationwide screening programmes for cystic fibrosis carriers in The Netherlands.
Methods
The costs of medical consumption of patients with cystic fibrosis were divided into costs of hospital care (hospital days, consultations, diagnostic tests), hospital and home medication, and home care (visits to a general practitioner, physiotherapy at home, help from relatives, diet, travelling expenses, and special aids). To gain insight into the medical consumption that is not covered in the medical records we asked 73 patients to keep a diary of visits to the general practitioner and physiotherapist, and travelling expenses for one month. The response rate of this questionnaire was 64%. We also questioned the patients about the support received from their social environment (for example, relatives), their daily activities, and their school/work life.
To check whether the medical consumption estimated from the medical records was in accordance with clinical experience, we interviewed several clinicians in charge of patients with cystic fibrosis. The results of the patient questionnaire were used to validate several data extracted from the patient records. The questionnaire itselfwas validated through interviews with some of the patients (or their parents) who completed the diaries.
The average age-specific medical consumption was obtained by dividing the age-specific consumption from the patient records and the patient questionnaires by the patient-years at risk in the age group concerned. Separate calculations were The average age-specific medical costs are obtained by multiplying the average agespecific medical consumption by the corresponding unit cost figures. The age-specific figures were converted into the lifetime average consumption by using the Sum-Limit method8 which corrects for the year-to-year survival of patients with cystic fibrosis. To discount these costs we used a 5% discount rate towards the time of birth. Survival of patients with cystic fibrosis in The Netherlands was estimated from the Dutch cystic fibrosis registration.
Results
The average consumption of the most important aspects of hospital care (except medication) is presented in table 2. "Consultations" include all visits of patients to the outpatients department. "Laboratory tests" represent the number of results of laboratory investigations (from blood, urine, and stool).
The estimates of the costs of home medication and home care were based on the patient questionnaire. Costs of home care include materials, diet, and travelling expenses. On average a patient visited the general practitioner Wildhagen, Verheij, Hilderink, Kooij, Tijmstra, ten Kate, Geritsen, Bakker, Habbema The average cost of a patient with cystic fibrosis per year is £10 908. Table 3 presents the breakdown of these costs. The total cost of care of cystic fibrosis in The Netherlands in 1991 is estimated to be £10-9 million, which is approximately 0 07% of the total health care budget in The Netherlands. This figure is obtained by multiplying the average costs per year with the number of patients (estimated at 1000 patients).
The cost of age-specific hospital care, medication, and home care is presented in the figure. The five year moving average is obtained by averaging the costs of the index year with the costs of the two preceding and the two following years. We have to keep in mind that from age 25 onwards our estimates are based on a relatively small group of patients (age . 25 years, n = 8).
A relatively high medical consumption occurs in the first year of life because the diagnostic process takes place in the first year of In order to arrive at the costs in The Netherlands we totalled the average cost per year of life up to the age of 35 which amounted to £614587. When survival is taken into consideration, the lifetime costs of a patient with cystic fibrosis are £409453. If we discount the lifetime costs to the time of birth using a discount rate of 5%, which is common in costeffectiveness studies, they amount to £164 365.
The difference in costs between the average medical consumption of patients aged 15 and older who are not in the (pre)terminal phase and the average medical consumption of patients in the (pre)terminal stage amounts to £26 599 which is 71% of the costs of the (pre)terminal stage (table 4) . This difference is due to the large number of hospital days, radiographs, Doppler studies, and laboratory tests that are required. It is noteworthy that there is no big difference between the average cost of care of all patients (£10 908) and the cost of care for patients older than 15 years who are not in the (pre)terminal phase (£11 102). This can be explained by the relatively small number of patients in the, (pre)-terminal phase (n=8) and the relatively low costs of patients under the age of 15 (£7759). Discussion This study has focused on patients with cystic fibrosis in The Netherlands. In order to compare our findings with those of others, temporary price fluctuations in currencies have to be eliminated. All costs presented in this study are converted to pounds sterling by using the purchasing power parity (PPP) according to the Big Mac index for the corresponding countries,'01' adjusted to 1991 by using average annual inflation rates. 2 The specific differences in health care organisation between countries are not considered in any PPP index (OECD or Big Mac). Van Ineveld calculated that the same set of health care services in the UK is 9% cheaper than in The Netherlands.'3 We did not take this into account. 
